GasLog Ltd. (GLOG) EPS Estimated At $0.06; Newlink Genetics (NLNK) Sentiment Is 1.22

February 15, 2018 - By Lawrence Diaz

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $251.01 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. It currently has negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.

Analysts expect GasLog Ltd. (NYSE:GLOG) to report $0.06 EPS on February, 16.They anticipate $0.04 EPS change or 200.00% from last quarter’s $0.02 EPS. GLOG’s profit would be $6.14 million giving it 81.46 P/E if the $0.06 EPS is correct. The stock increased 5.11% or $0.95 during the last trading session, reaching $19.55. About 409,989 shares traded or 3.47% up from the average. GasLog Ltd. (NYSE:GLOG) has risen 20.14% since February 15, 2017 and is uptrending. It has outperformed by 3.44% the S&P500.

Among 13 analysts covering GasLog (NYSE:GLOG), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. GasLog has $26 highest and $7 lowest target. $18.48’s average target is -5.47% below currents $19.55 stock price. GasLog had 33 analyst reports since August 7, 2015 according to SRatingsIntel. Stifel Nicolaus maintained GasLog Ltd. (NYSE:GLOG) rating on Thursday, November 2. Stifel Nicolaus has “Buy” rating and $19.0 target. The firm has “Neutral” rating given on Monday, February 22 by Citigroup. As per Wednesday, April 26, the company rating was initiated by Credit Suisse. JP Morgan downgraded the shares of GLOG in report on Wednesday, March 16 to “Underweight” rating. The stock of GasLog Ltd. (NYSE:GLOG) earned “Neutral” rating by Seaport Global Securities on Wednesday, November 23. The stock of GasLog Ltd. (NYSE:GLOG) has “Buy” rating given on Wednesday, February 15 by Citigroup. The rating was maintained by Stifel Nicolaus on Sunday, October 22 with “Buy”. The stock of GasLog Ltd. (NYSE:GLOG) has “Overweight” rating given on Tuesday, June 13 by Morgan Stanley. Seaport Global Securities upgraded GasLog Ltd. (NYSE:GLOG) on Tuesday, February 21 to “Buy” rating. The company was maintained on Thursday, August 3 by Cowen & Co.

GasLog Ltd. operates as an owner, operator, and manager of liquefied natural gas carriers. The company has market cap of $2.00 billion. As of March 1, 2017, it owned a fleet of 27 LNG carriers, including 22 ships on the water and 5 on order, as well as had an LNG carrier leased back under a long-term bareboat charter. It has a 56.67 P/E ratio. The firm also offers technical ship management services for LNG carriers owned by third parties.

Redmile Group Llc holds 0.63% of its portfolio in NewLink Genetics Corporation for 1.25 million shares. Perceptive Advisors Llc owns 450,000 shares or 0.17% of their US portfolio. Moreover, Rhenman & Partners Asset Management Ab has 0.13% invested in the company for 100,000 shares. The New York-based Pdt Partners Llc has invested 0.12% in the stock. Endurant Capital Management Lp, a California-based fund reported 36,100 shares.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>